One company, purpose-built to
achieve a goal that the industry
has been seeking for a long time:
"... this merger should be a big plus for small Biotech to have additional commercial options."
"The combination of INC Research and inVentiv will expand our global scale and add capabilities to grow our addressable market."
- A. Macdonald, CEO
"... INCR's deep therapeutic expertise combined with inVentiv's FSP and CCO capabilities should provide a compelling solution..."
- Wall Street Analyst
"The new organization's combined clinical scale, therapeutic depth and expertise will allow it to partner with biopharmaceutical companies of all sizes..."
- Wall Street Analyst
“…this merger has significant customer advantages as it deepens our scale, scope and therapeutic expertise.”
- M. Bell, Executive Chairman of the Board of Directors
and President, Commercial Division
INC Research/inVentiv Health Strengthens Leadership of Commercial Solutions, Michelle Keefe Appointed President, Commercial SolutionsRead The Release
Investigative Sites Honor INC Research/inVentiv Health with 2017 Society for Clinical Research Sites Eagle AwardRead The Release
INC Research/inVentiv Health Report Evaluates How Payers and Manufacturers Can Find Common Ground in Rare DiseasesRead The Report
inVentiv Health was built to address your specific challenges. From clinical development to commercialization, we are facilitators with passion, drive and endless energy to help bring your product from concept to reality.
To learn more about how inVentiv Health experts can help you, please contact us by clicking here.Contact Us
inVentiv Health has been made aware of an internet scam targeting job seekers who have posted their resumes on job posting websites. Scammers are contacting applicants via email and purporting to represent inVentiv Health. Many of these scammers are using Gmail accounts and Google Hangouts to communicate with applicants. All correspondence with us comes from an internal employee with a valid @inventivhealth.com email address. Anyone who suspects they have been solicited in this scam should contact the FBI at ic3.gov.